The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
TRAIL on trial: preclinical advances in cancer therapy
Open accessAbstract
TNF-related apoptosis-inducing ligand, or TRAIL, is a promising anti-cancer agent as it can induce apoptosis in a wide range of cancers whilst generally sparing non-malignant cells. However, the translation of TRAIL into the clinic has been confounded by its short half-life, inadequate delivery methods and TRAIL-resistant cancer cell populations. In this review we discuss how TRAIL has been functionalized to diversify its traditional tumor-killing role and novel strategies to facilitate its effective deployment in preclinical cancer models. The successes and failures of the most recent clinical trials using TRAIL agonists are discussed and we provide a perspective for improving its clinical implementation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497 · cited 1×
“Examples of this strategy include addition of a FLAG tag (FLAG-TRAIL[19]), leucine or isoleucine zipper (LZ-TRAIL[8]; iz-TRAIL[20, 21]) or a tanascin-C (TNC) oligomerization domain (TNCTRAIL[22]).”
BackgroundSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Programmed Cell Death in Animal Development and Disease
Fuchs, Y., & Steller, H. (2011) · Cell · doi:10.1016/j.cell.2011.10.033 · Cited by 1,915 · cited 1×
“Apoptosis is an essential event in maintaining tissue homeostasis by eliminating harmful cells from the body[10].”
BackgroundJohnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Lessons from the Cancer Genome
Garraway, L. A., & Lander, E. S. (2013) · Cell · doi:10.1016/j.cell.2013.03.002 · Cited by 1,308
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834
Death receptor-induced cell killing
Thorburn, A. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2003.08.007 · Cited by 791
Mitochondria: master regulators of danger signalling
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3479 · Cited by 733
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610
Single domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 552
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Caspase-8 and Bid: Caught in the act between death receptors and mitochondria
Kantari, C., & Walczak, H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.026 · Cited by 502
TRAIL signalling: Decisions between life and death
Falschlehner, C., Emmerich, C. H., Gerlach, B., & Walczak, H. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.007 · Cited by 458
Sasportas, L. S., Kasmieh, R., Wakimoto, H., Hingtgen, S., van de Water, J. A. J. M., Mohapatra, G., Figueiredo, J. L., Martuza, R. L., Weissleder, R., & Shah, K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806647106 · Cited by 455
Self-citationClinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Liu, T.-C., Galanis, E., & Kirn, D. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0736 · Cited by 450
Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnya, T. M., Lum, B. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1991 · Cited by 446
Kelley, S. K., Harris, L. A., Xie, D., DeForge, L., Totpal, K., Bussiere, J., & Fox, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29298-3 · Cited by 445
Ashkenazi, A., Holland, P., & Eckhardt, S. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7198 · Cited by 421
Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417
Corsten, M. F., Miranda, R., Kasmieh, R., Krichevsky, A. M., Weissleder, R., & Shah, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1045 · Cited by 406
Self-citationMeasuring and Modeling Apoptosis in Single Cells
Spencer, S. L., & Sorger, P. K. (2011) · Cell · doi:10.1016/j.cell.2011.03.002 · Cited by 336
Mesenchymal stem cells engineered for cancer therapy
Shah, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.010 · Cited by 322
Self-citationDimberg, L. Y., Anderson, C. K., Camidge, R., Behbakht, K., Thorburn, A., & Ford, H. L. (2013) · Oncogene · doi:10.1038/onc.2012.164 · Cited by 276
Oncolytic herpes simplex virus vectors for cancer virotherapy
Varghese, S., & Rabkin, S. D. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700537 · Cited by 264
Kauer, T. M., Figueiredo, J.-L., Hingtgen, S., & Shah, K. (2012) · Nature Neuroscience · doi:10.1038/nn.3019 · Cited by 236
Self-citationGanten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., & Walczak, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2635 · Cited by 217
Gene and doxorubicin co-delivery system for targeting therapy of glioma
Liu, S., Guo, Y., Huang, R., Li, J., Huang, S., Kuang, Y., Han, L., & Jiang, C. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.031 · Cited by 203
Hotte, S. J., Hirte, H. W., Chen, E. X., Siu, L. L., Le, L. H., Corey, A., Iacobucci, A., MacLean, M., Lo, L., Fox, N. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1416 · Cited by 190
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M. M., Fox, N. L., Miceli, R. C., Ullrich, S. J., Fisher, G. A., & Tolcher, A. W. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp292 · Cited by 157
Forero, A., Shah, J. J., Wood, T. E., Posey, J. A., Carlisle, R. R., Copigneaux, C., Luo, F. M., Wojtowicz‐Praga, S., Percent, I. J., & Saleh, M. N. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0673 · Cited by 150
TRAIL Signaling and Synergy Mechanisms Used in TRAIL-Based Combination Therapies
Hellwig, C. T., & Rehm, M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0434 · Cited by 150
Kim, S. M., Oh, J. H., Park, S. A., Ryu, C. H., Lim, J. Y., Kim, D., Chang, J. W., Oh, W., & Jeun, S. (2010) · Stem Cells · doi:10.1002/stem.543 · Cited by 142
Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare
Corsten, M. F., & Shah, K. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70099-8 · Cited by 138
Self-citationA Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
Younes, A., Vose, J. M., Zelenetz, A. D., Smith, M. R., Burris, H. A., Ansell, S. M., Klein, J., Halpern, W., Miceli, R. C., Kumm, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605987 · Cited by 132
Berg, D., Lehne, M., Müller, N., Siegmund, D., Münkel, S., Sebald, W., Pfizenmaier, K., & Wajant, H. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402213 · Cited by 130
Nanobody; an Old Concept and New Vehicle for Immunotargeting
Rahbarizadeh, F., Ahmadvand, D., & Sharifzadeh, Z. (2011) · Immunological Investigations · doi:10.3109/08820139.2010.542228 · Cited by 117
Production of Recombinant TRAIL and TRAIL Receptor: Fc Chimeric Proteins
Schneider, P. (2000) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(00)22031-4 · Cited by 113
Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors
Martínez‐Quintanilla, J., Bhere, D., Heidari, P., He, D., Mahmood, U., & Shah, K. (2013) · Stem Cells · doi:10.1002/stem.1355 · Cited by 103
Self-citationSayers, T. J., & Murphy, W. J. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0676-3 · Cited by 102
Choi, S. A., Hwang, S.-K., Wang, K.-C., Cho, B.-K., Phi, J. H., Lee, J. Y., Jung, H., Lee, D. H., & Kim, S. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq147 · Cited by 97
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
van de Water, J. A. J. M., Onder, T. B., Agarwal, A. S., Wakimoto, H., Roovers, R. C., Zhu, Y., Kasmieh, R., Bhere, D., Henegouwen, P. M. P. V. B. E., & Shah, K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202832109 · Cited by 95
Self-citationRegulation of the human TRAIL gene
Allen, J. E., & El‐Deiry, W. S. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21354 · Cited by 90
Hu, Y., Huang, B., Zhang, T., Miao, P., Tang, G., Tabata, Y., & Gao, J. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300254s · Cited by 90
Inducible Release of TRAIL Fusion Proteins from a Proapoptotic Form for Tumor Therapy
Shah, K., Tung, C., Yang, K. S., Weissleder, R., & Breakefield, X. O. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3516 · Cited by 89
Self-citationBangert, A., Cristofanon, S., Eckhardt, I., Abhari, B. A., Kolodziej, S., Häcker, S., Vellanki, S. H., Lausen, J., Debatin, K., & Fulda, S. (2012) · Oncogene · doi:10.1038/onc.2011.614 · Cited by 87
Radiation Increases Invasion of Gene-Modified Mesenchymal Stem Cells into Tumors
Zielske, S. P., Livant, D. L., & Lawrence, T. S. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.06.1953 · Cited by 86
Kim, S. W., Kim, S. J., Park, S. H., Yang, H. G., Kang, M. C., Choi, Y. W., Kim, S. M., Jeun, S., & Sung, Y. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1568 · Cited by 83
Superior serum half life of albumin tagged TNF ligands
Müller, N., Schneider, B., Pfizenmaier, K., & Wajant, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.134 · Cited by 76
Stieglmaier, J., Bremer, E., Kellner, C., Liebig, T. M., ten Cate, B., Peipp, M., Schulze‐Koops, H., Pfeiffer, M. M., Bühring, H., Greil, J., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0370-8 · Cited by 75
Perlstein, B., Finniss, S., Miller, C. G., Okhrimenko, H., Kazimirsky, G., Cazacu, S., Lee, H. K., Lemke, N. W., Brodie, S., Umansky, F., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos248 · Cited by 73
Reagan, M. R., Seib, F. P., McMillin, D. W., Sage, E. K., Mitsiades, C. S., Janes, S. M., Ghobrial, I. M., & Kaplan, D. L. (2012) · Journal of Breast Cancer · doi:10.4048/jbc.2012.15.3.273 · Cited by 70
Engineering death receptor ligands for cancer therapy
Wajant, H., Gerspach, J., & Pfizenmaier, K. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.12.019 · Cited by 67
Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro
Schichor, C., Albrecht, V. S., Korte, B. G., Büchner, A., Riesenberg, R., Mysliwietz, J., Paron, I., Motaln, H., Turnšek, T. L., Jürchott, K., et al. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.12.033 · Cited by 61
Kim, T. H., Jo, Y. G., Jiang, H. H., Lim, S. M., Youn, Y. S., Lee, S., Chen, X. S., Byun, Y., & Lee, K. C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.021 · Cited by 61
Kim, T. H., Youn, Y. S., Jiang, H. H., Lee, S., Chen, X. S., & Lee, K. C. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200187k · Cited by 58
Hingtgen, S., Kasmieh, R., van de Water, J. A. J. M., Weissleder, R., & Shah, K. (2010) · Stem Cells · doi:10.1002/stem.313 · Cited by 56
Self-citationMultimechanistic Tumor Targeted Oncolytic Virus Overcomes Resistance in Brain Tumors
Tamura, K., Wakimoto, H., Agarwal, A. S., Rabkin, S. D., Bhere, D., Martuza, R. L., Kuroda, T., Kasmieh, R., & Shah, K. (2012) · Molecular Therapy · doi:10.1038/mt.2012.175 · Cited by 56
Self-citationResistance to TRAIL and how to surmount it
Maksimović‐Ivanić, D., Stošić‐Grujičić, S., Nicoletti, F., & Mijatović, S. (2012) · Immunologic Research · doi:10.1007/s12026-012-8284-8 · Cited by 55
Norian, L. A., Kresowik, T. P., Rosevear, H. M., James, B. R., Rosean, T. R., Lightfoot, A. J., Kucaba, T. A., Schwarz, C., Weydert, C. J. D., Henry, M. D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031085 · Cited by 52
Combined modality therapy with TRAIL or agonistic death receptor antibodies
Amm, H. M., Oliver, P. G., Lee, C. H., Li, Y., & Buchsbaum, D. J. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.5.14671 · Cited by 50
Camidge, D. R. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1167 · Cited by 49
Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules
Piras, V., Hayashi, K., Tomita, M., & Selvarajoo, K. (2011) · Scientific Reports · doi:10.1038/srep00144 · Cited by 37
Jiang, M.-H., Liu, Z., Xiang, Y., Ma, H., Liu, S.-L., Liu, Y.-X., & Zheng, D. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-54 · Cited by 37
Kim, H., Jeong, D., Kang, H. E., Lee, K. C., & Na, K. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01564.x · Cited by 24
Duiker, E. W., Dijkers, E. C. F., Heerspink, H. J. L., de Jong, S., van der Zee, A., Jager, P. L., Kosterink, J. G. W., de Vries, E., & Hooge, M. N. L. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01718.x · Cited by 20
Combination antibody‐based cancer immunotherapy
Takeda, K., Okumura, K., & Smyth, M. J. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00529.x · Cited by 20
Lee, H. J., Yang, H.-M., Choi, Y., Park, S., Moon, S., Lee, Y., Sung, Y. C., & Kim, S. J. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182710401 · Cited by 14
Zhang, H., Sui, A., Wang, Z.-L., Liu, S., & Yao, R. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.998 · Cited by 12
Cited by
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Liang, J., Hänsch, G. M., Hübner, K., & Samstag, Y. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.11.006 · Cited by 72
Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells
Shlyakhtina, Y., Pavet, V., & Gronemeyer, H. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.423 · Cited by 56
Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model
Pessina, A., Leonetti, C., Artuso, S., Benetti, A., Dessy, E., Pascucci, L., Passeri, D., Orlandi, A., Berenzi, A., Bonomi, A., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0200-3 · Cited by 39
“Although the presence of some conflicting data [52, 53], in general preclinical studies indicate that MSCs loaded with anti-cancer molecules could be very effective to inhibit primary and metastatic cancer growth [3–6].”
BackgroundIntracranial delivery of synthetic mRNA to suppress glioblastoma
Peng, H., Guo, X., He, J., Duan, C., Yang, M., Zhang, X., Zhang, L., Fu, R., Wang, B., Wang, D., et al. (2022) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2021.12.010 · Cited by 30
Metadata
- Authors
- Stuckey, D. W., & Shah, K.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 19
- Issue
- 11
- Pages
- 685-694
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2129305290
- Cited by
- 276
- References
- 73
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.